Quotient Therapeutics has developed a Somatic Genomics platform that unveils a new universe of genetic variation to create transformational medicines. Here are details of Quotient Therapeutics‘s latest funding round :
🚀 Launch
…
🏭 Industry
Biotechnology
🧠Management
Geoffrey von Maltzahn (CEO)
💸 Funding & Investors
| INVESTMENT (Novembre 2023) | $50 million |
| INVESTORS (Novembre 2023) | led by Flagship Pioneering |
🎯 Funding purpose
Advance development of its platform.
🌐 Country HQ
UK (Cambridge)